Clinical

Dataset Information

0

Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study

ABSTRACT: Primary outcome(s): Overall survival

DISEASE(S): Colorectal Cancer

PROVIDER: 2635694 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study.
| S-EPMC10340604 | biostudies-literature
Unknown Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan.
| S-EPMC7292354 | biostudies-literature
Unknown Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy.
| S-EPMC7599669 | biostudies-literature
Unknown Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
| S-EPMC5759812 | biostudies-literature
Unknown Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study.
| S-EPMC8350191 | biostudies-literature
Unknown Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer.
| S-EPMC11618181 | biostudies-literature
Clinical Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
| 2126073 | ecrin-mdr-crc
Unknown Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
| S-EPMC5834058 | biostudies-literature
Unknown Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
| S-EPMC6909918 | biostudies-literature
Unknown TAS-102 Plus Bevacizumab as an Effective and Well Tolerated Regimen in Chemotherapy-Refractory Advanced Colorectal Cancers - A Single Institution Retrospective Analysis.
| S-EPMC12714468 | biostudies-literature